Type 2 diabetes mellitus treatment adjunct

Type 2 diabetes mellitus is a chronic metabolic disorder characterized by systemic hyperglycemia resulting from peripheral insulin resistance coupled with progressive pancreatic beta-cell dysfunction This condition impairs glucose regulation across multiple organ systems, predominantly affecting skeletal muscle, liver, and adipose tissues

Type 2 diabetes mellitus is a chronic metabolic disorder characterized by systemic hyperglycemia resulting from peripheral insulin resistance coupled with progressive pancreatic beta-cell dysfunction This condition impairs glucose regulation across multiple organ systems, predominantly affecting skeletal muscle, liver, and adipose tissues In this clinical state, adjunctive management aims to mitigate persistent hyperglycemia and prevent associated microvascular and macrovascular complications

As an indication qualifier, a "treatment adjunct" denotes a therapeutic agent indicated for use alongside standard non-pharmacologic interventions—specifically medical nutrition therapy and structured physical activity—or complementary antihyperglycemic therapies to achieve target glycemic control

As an indication qualifier, a "treatment adjunct" denotes a therapeutic agent indicated for use alongside standard non-pharmacologic interventions—specifically medical nutrition therapy and structured physical activity—or complementary antihyperglycemic therapies to achieve target glycemic control

In this clinical state, adjunctive management aims to mitigate persistent hyperglycemia and prevent associated microvascular and macrovascular complications